-
A Personal Perspective on Ethics vs. Profits Recently, I had a candid conversation with the Sales VP of a mid-size biotech company. We debated an issue that’s becoming increasingly central in business development: pricing transparency. When I shared my belief that offering clear, consistent, and ethical pricing would build stronger trust and partnerships, they pushed…
-
Overview In biotech due diligence, the stakes are high. While due diligence checklists are crucial for documenting a company’s clinical, scientific, and operational information, they often miss subtle signs of potential failure or untapped breakthroughs. This case study explores how a biotech investor used advanced qualitative analysis to uncover a hidden breakthrough and avoid a…
-
A sample due diligence case from the perspective of PlexoA’s scientific advisory team. Scenario A venture capital (VC) firm is considering a $2M seed investment in a startup developing a bispecific antibody designed to redirect T cells to attack solid tumors. The startup’s lead asset, called TCX-101, binds to a tumor antigen found in ovarian…
-
A sample due diligence case from the perspective of PlexoA’s scientific advisory team. Background A mid-sized pharmaceutical company was scouting new RNA platforms to license for their rare disease pipeline. A biotech startup had caught their attention with a proprietary siRNA delivery system, claiming improved tissue specificity and reduced immune activation. The pharma team was…
-
A sample due diligence case from the perspective of PlexoA’s scientific advisory team. Background An AI-driven drug discovery startup had generated investor buzz by claiming to identify novel therapeutic targets for neurodegenerative diseases using machine learning on multi-omic datasets. The targets were said to be “biologically novel, mechanistically relevant, and druggable.” But when one of…
-
A sample due diligence case from the perspective of PlexoA’s scientific advisory team. Background A venture capital firm was evaluating a CNS-focused biotech startup preparing for its Series A raise. The company claimed to have developed a novel nanoparticle platform that could cross the blood-brain barrier (BBB) and deliver small molecules directly to neural tissues.…
-
As we navigate the complex landscape of biotechnology in 2025, breaking into the biotech market remains both a challenging and rewarding endeavor. The industry continues to evolve rapidly, driven by groundbreaking scientific advancements and an ever-increasing demand for innovative healthcare solutions. For companies aiming to carve out their niche in this competitive sector, understanding and…
-
In the ever-evolving landscape of biotechnology, optimizing research and development (R&D) portfolios has become a critical challenge for industry leaders. As we navigate through 2025, the pressure to innovate while managing risks and maximizing returns has never been more intense. Biotech companies face a complex array of decisions, from selecting promising drug candidates to allocating…
-
In the rapidly evolving landscape of biopharmaceuticals, market analysis has emerged as a critical cornerstone for success. As we navigate through 2025, the importance of understanding market dynamics, patient needs, and competitive forces has never been more pronounced. Market analysis serves as the compass guiding biopharma companies through the complex maze of drug development, regulatory…
-
In the rapidly evolving landscape of biotechnology, data has emerged as the new currency driving innovation and growth. As we navigate through 2025, the integration of data-driven strategies has become not just an advantage, but a necessity for biotech companies aiming to stay competitive. From drug discovery to clinical trials and market analysis, the power…